About this trial
The main objective is to evaluate the efficacy of IV administration of the P2Y12 inhibitor (cangrelor) in addition to mecanich thrombectomy and WMD versus mecanich thrombectomy and WMD alone on the functional prognosis at 3 months, in patients with acute ischemic stroke eligible for mecanich thrombectomy on the basis of infusion imaging between 0 and 24 hours after the onset of symptoms.
Eligibility criteria
Qualifiers
Age 18 or older
Anterior circulation intracanial large artery occlusion isolated (Intracranial ICA and/or MCA) proved on CTA or MRA.
Symptoms onset < 24h at imaging
Perfusion imaging: An initial infarct volume (ischemic core on DWI or CTP calculated by the RAPID software) of less than 70 ml, a ratio between the critically hypoperfused lesion volume (calculated by RAPID with a TMax>6s) and initial infarct volume of 1.8 or more, and an absolute difference between those 2 volumes of 15 ml or more.
Disqualifiers
Contraindication to MT
Patient over 80 years old with >10 microbleeds on pre-treatment MRI
Pre-existing dependency with mRS ≥3.
Known tandem ICA-MCA occlusions requiring stenting
Trial design
Treatments tested in this trial
- Cangrelor
- best medical management
Treatment groups
Sponsors and collaborators
Fondation Ophtalmologique Adolphe de Rothschild
Lead sponsor
Ministry of Health, France
Collaborator